Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Missouri for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Missouri only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Missouri (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Benjamin Tan (NPI 1275551814)

Field	Value
Entity Type	Individual
Organization	Benjamin Tan
Address	4921 Parkview Pl
City	Saint Louis
State	MO
ZIP	63110
Taxonomy	Medical Oncology Physician
NPI Enumerated	July 18, 2006

Payer Source	Total Paid
Medicare	$1.3M
Medicaid	$0

Key Findings

This provider’s billing footprint is concentrated in Medicare with Total Medicare revenue: $1.3M and Total Medicaid revenue: none (no Medicaid billing on file); operationally the practice appears effectively single-payer from the available claims data and therefore most commercial/Medicaid exposure would be absent or routed through other entities. The lack of any Medicaid billing on file suggests the provider either does not treat Medicaid patients directly or bills Medicaid under a different group NPI.

Revenue is highly concentrated in a small set of high-cost oncology drug codes: the precomputed top-3 codes account for 78.5% of this provider’s total Medicare revenue, driven primarily by J9299 (40.5%, $505K), J9271 (31.1%, $387K), and J0897 (6.8%, $85.3K). This concentration indicates the practice’s financial performance is substantially dependent on a few oncology biologics rather than on office E/M or procedure volume.

The code mix and descriptions are consistent with a medical oncology infusion practice focused on immune checkpoint inhibitors and supportive therapies: J9299 (nivolumab) and J9271 (pembrolizumab) dominate revenue, while J0897 (denosumab), J2506 (pegfilgrastim, $30.1K, 2.4%), and chemotherapy administration codes such as 96413 ($44.8K, 3.6%) and G0498 ($11.4K, 0.9%) support an infusion-centered service line. Clinical activity appears drug-product driven — the highest revenue items are the injectable therapies themselves rather than E/M codes (for example, 99214 generated $24.5K, 2.0%).

Competitive standing by code shows a mixed national position: J9299 ranks #149 of 505 providers nationally (71th percentile; typical, unremarkable volume), indicating a solid but not dominant presence for nivolumab; J9271 ranks #1299 of 1841 providers nationally (29th percentile; typical, unremarkable volume), reflecting a more modest pembrolizumab footprint; and J0897 ranks #2971 of 10057 providers nationally (70th percentile; typical, unremarkable volume), which is a respectable showing for denosumab. Overall, the provider is not a top national outlier but has notable specialization in specific oncology drugs that produce most of its Medicare revenue.

Claims-level patterns reflect per-milligram billing common in oncology injectables: very high claim counts with low average paid per claim are evident for the top drugs (J9299: 21K claims, $24 avg paid/claim; J9271: 9K claims, $43 avg paid/claim), which is consistent with billing by small per-unit increments rather than single-dose codes and explains why medication line items dominate revenue despite modest average per-claim payments. This operational detail is important for payers assessing utilization management, per-unit adherence, and budget impact from biologic dosing practices.

Ancillary infusion and supportive codes are present but represent a small share of revenue compared with the drugs themselves — examples include 96413 (448 claims, $44.8K, 3.6%), 96367 (299 claims, $6.9K, 0.6%), and 96365 (71 claims, $3.4K, 0.3%). The presence of these administration and add-on codes confirms in-office or clinic-based infusion capability, yet administration fees are a minority of the Medicare revenue stream, reinforcing that drug acquisition/dispensing is the primary cost center.

The provider’s NPI tenure (NPI enumerated (registered): 2006-07-18 (~20 years ago)) indicates long-standing enrollment in Medicare, which supports continuity of claims data over time and suggests established practice operations. For contracting or network planning, this tenure combined with a drug-centric revenue profile signals an experienced oncology clinician whose financial exposure is concentrated in specific biologic therapies rather than broad ambulatory E/M services.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

49 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9299	Injection, nivolumab, 1 mg	21,040	$20	$505K
J9271	Injection, pembrolizumab, 1 mg	9,000	$40	$387K
J0897	Injection, denosumab, 1 mg	4,740	$20	$85.3K
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	1,430	$40	$54.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	450	$100	$44.8K
J3315	Injection, triptorelin pamoate, 3.75 mg	140	$290	$40.9K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	370	$80	$30.1K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	250	$100	$24.5K
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community…	90	$130	$11.4K
J1439	Injection, ferric carboxymaltose, 1 mg	9,000	$1	$9K

Showing 1–10 of 49

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 49 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Missouri Distribution

Benjamin Tan — 0 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Missouri

Full comparison — all codes billed, vs. state median

49 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	23	40	9,100	$40	$502K
J9299	3	20	14,170	$20	$360.3K
J1561	19	30	1,650	$40	$87.1K
J0897	48	210	2,400	$20	$82.4K
J3315	2	10	140	$290	$40K
J2506	12	40	310	$80	$25.9K
J1439	17	20	21,000	$1	$22.2K
96413	21	160	140	$100	$19.1K
J3490	17	80	40	$150	$14K
99214	2,072	8,960	100	$80	$13.9K

Showing 1–10 of 49

Related Providers

Other providers that share a Tax Identification Number (TIN) with Benjamin Tan, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Washington University	MO	Multi-Specialty Clinic/Center	$0	$22M
Washington University	MO	Multi-Specialty Clinic/Center	$0	$14.8M
Washington University	MO	Multi-Specialty Clinic/Center	$0	$10.4M
Washington University	MO	Emergency Care Clinic/Center	$0	$9.1M
Washington University	MO	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$6.9M
Washington University	MO	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$4.4M
Washington University	MO	Multi-Specialty Clinic/Center	$0	$4M
John Visconti	IL	Medical Oncology Physician	$2.8M	$149.1K
Peter Oppelt	MO	Medical Oncology Physician	$2.5M	$15.8K
Ronald Dean	MT	Emergency Medicine Physician	$2.3M	$2.3K

Nearby Providers

Other providers in the same ZIP code as Benjamin Tan, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Council For Extended Care	MO	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$98.1M
St. Louis Children's Hospital	MO	Children's Hospital	$0	$66.9M
Barnes Jewish Hospital	MO	General Acute Care Hospital	$0	$61.4M
Paraquad Inc	MO	Customized Equipment (DME)	$0	$56.3M
Cooperative Home Care, Inc.	MO	Home Health Agency	$0	$20.6M
New Beginnings In Home Services, LLC	MO	In Home Supportive Care Agency	$0	$11.6M
Bjc Home Care Services	MO	Durable Medical Equipment & Medical Supplies	$0	$8.2M
Wallace Family In Home Health LLC	MO	In Home Supportive Care Agency	$0	$6.6M
Cooperative Home Care	MO	Home Health Agency	$0	$5.5M
Josephines Caring Hands	MO	In Home Supportive Care Agency	$0	$3.4M

Benjamin Tan — Billing Profile & Reimbursement Data

Sign up for Benjamin Tan — Billing Profile & Reimbursement Data policy alerts

Benjamin Tan — Billing Profile & Reimbursement Data

Sign up for Benjamin Tan — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References